Annexon, Inc. (ANNX) Dividend History

Annexon, Inc. is a biotechnology company focused on developing therapies for neurodegenerative and autoimmune diseases. It specializes in targeting the complement system to address conditions such as Alzheimer’s disease, multiple sclerosis, and other immune-related disorders. The company's approach involves creating monoclonal antibodies that modulate the immune response to prevent cellular damage.

1400 Sierra Point Parkway, Brisbane, CA, 94005
Phone: (650)-822-5500
Website: https://www.annexonbio.com

Dividend History

Annexon, Inc. currently does not pay dividends

Company News

Huntington’s Disease Clinical Trial Pipeline Analysis: 20+ Key Companies Shaping the Future of Dopamine Receptor Antagonists Therapeutics | DelveInsight

The Huntington's disease treatment market is poised for significant growth, driven by rising prevalence rates, advancements in gene-targeting and disease-modifying therapies, and a robust clinical pipeline addressing critical unmet needs.

GlobeNewswire Inc.

Featured Companies: ALNY
Annexon Announces Presentations on the Clinical Advancement of Tanruprubart as the First Potential Targeted Therapy for Guillain-Barré Syndrome (GBS) at the 2025 PNS Meeting

Annexon announced presentations at the 2025 PNS Meeting highlighting improved outcomes with its investigational therapy tanruprubart for the treatment of Guillain-Barré Syndrome (GBS), a rare autoimmune disease with no approved treatments.

GlobeNewswire Inc.
Annexon Highlights Leadership in Advancing Clinical Research and Education for Guillain-Barré Syndrome (GBS) at American Academy of Neurology (AAN) 2025 Annual Meeting

Annexon, a biopharmaceutical company, is presenting data on its Phase 3 trial for ANX005, a potential treatment for Guillain-Barré Syndrome (GBS), at the AAN 2025 Annual Meeting. The company is also launching a disease education campaign to raise awareness about the impact of GBS.

GlobeNewswire Inc.
Annexon Biosciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Annexon, Inc., a biopharmaceutical company, announced that its president and CEO will present at the upcoming J.P. Morgan Healthcare Conference. The company is focused on developing novel therapies for classical complement-mediated neuroinflammatory diseases.

GlobeNewswire Inc.
Annexon to Present Additional Phase 2 Data Showing Preservation of Visual Function and Structure by ANX007 in Geographic Atrophy at the 42nd ASRS Annual Scientific Meeting - GlobeNewswire

Annexon announced it will present data from the Phase 2 ARCHER trial of its drug candidate ANX007 for the treatment of geographic atrophy, an advanced form of dry age-related macular degeneration. The data shows ANX007 provided statistically significant protection against vision loss and preservation of key retinal structures.

GlobeNewswire Inc.

Dividend data last updated 06/07/2025 00:34:17 UTC